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Human organs are enormously complex, involving specialized struc-
tures, cells, and tissues that interact to carry out unique functionsical Engineering, Binghamton
tates.
r).
. This is an open access article underessential to survival. Due to this complexity, it's no wonder that there
is currently a lack of reliable model systems to recapitulate tissue and
organ level functions in the lab. In the past, researchers were left with
two options: Static, in vitro cultures of human cells (primary or from
cell lines), or the use of animal models; however, both of these options
have ﬂaws. In the case of human cell studies, primary cells are difﬁcult
to extract from tissues as a homogeneous population. They are also sen-
sitive to passaging, resulting in early senescence, altered phenotype andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ticated techniques and advanced training. To overcome passaging and
culturing issues, immortalized cells are often used. These cells are easy
to grow, and can be expanded to many passages, however the immor-
talization procedure results in cells with signiﬁcant changes that have
not yet been studied with enough depth to truly identify differences
from primary cell behavior (Astashkina et al., 2012). The most para-
mount issue with in vitro cell culture however, is the lack of physiolog-
ical growth conditions that are found in vivo. To overcome this issue,
animal models are often utilized, which leads to an entirely different
set of limitations. The use of animal test subjects is expensive, lengthy,
and at times controversial due to the question as to whether or not an-
imal data can be extrapolated to human systems (Esch et al., 2011). Ad-
ditionally, there is an innate lack of ability to study single factor changes
inwhole-body systemsdue to the sheer complexity of a livingorganism.
It is clear that advances to in vitro culturingmethods need to bemade to
bridge the gap between animal studies and cell culturing studies to ad-
dress these issues.
Within the last few decades, major advances have been made in
microﬂuidic technologies—speciﬁcally with their applications in organ-
on-a-chip devices. The term microﬂuidics refers to a set of technologies
that allow for the movement or manipulation of small volumes of liquid
or gas. The synergy of microengineering and tissue engineering allows
for the fabrication of growth environments that draw from the beneﬁts
of both human cell culture studies and animal models, supporting the
growth of human cells in physiologically relevant conditions (Bhatia
and Ingber, 2014; Schaffner et al., 1995). The term “organ-on-a-chip”
has origins in the semiconductor industry where microﬂuidic technolo-
gies began, prior to being adapted and expanded by the micro-
electromechanical systems (MEMS) ﬁeld. Early devices were fabricated
from glass (Harrison et al., 1992) and silicon (Van Lintel et al., 1988) in
a modiﬁed form of photolithographic etching that was used in the
manufacturing of computer chips, thus the “chip” in organ-on-a-chip.
Thesematerials are brittle, and require access to sophisticated fabrication
tools. The development of easy and inexpensive prototyping techniques
that utilized elastomermaterials allowed researchers to explore the ben-
eﬁts of on-chip tissue culture formany different tissues (Sackmann et al.,
2014).
Microﬂuidic technologies are able to exploit fundamental differences
between the physical properties of ﬂuids moving in macroscale systems
and those in micrometer-scale channels. First, microﬂuidic channels can
re-create ﬂuidic characteristics that we ﬁnd at the tissue level in vivo.
Withinmicroﬂuidic channels there is an immense difference in ﬂuid tur-
bulence compared to macroscale ﬂuidic systems. In large scale systems,
where inertia dominates viscous forces, ﬂuids mix convectively. In con-
trast to this, microscale systems, like microcapillaries in tissues, have
highly laminar ﬂow. Second, the laminar ﬂow allows for the generation
of physical and chemical gradients and highly controlled ﬂuid ﬂowwith-
in microﬂuidic devices, making them attractive platforms for organ-on-
a-chip devices. For example, when ﬂuids come together in a channel,
they ﬂow in parallel and the only ﬂuid mixing is due to diffusion across
theﬂuid interface (Kamholz and Yager, 2001). This leads to very predict-
able and controllable ﬂuid interactions through the addition of obstacles
or mixing apparatuses into channels to cause perturbations in ﬂow.
Third, microfabricated tissue scaffolds can be incorporated into
microﬂuidic systems, providing more in vivo-like microenvironments
where tissues can replicate amore in vivo-like architecture. Fourth, with-
inmicroﬂuidic systems, the liquid-to-cell ratios aremuch smaller than in
typical well plates. This allows for growth factors to accumulate and af-
fect tissue morphology and function. Additionally, capillary forces and
surface and interfacial tension dominate over gravity in microscale sys-
tems, allowing for the passive driving of ﬂuids through channels in oppo-
sition to gravity (Squires and Quake, 2005; Sung et al., 2010).
The goal of organ-on-a-chip devices is to recapitulate tissue- and
organ-level functions in a simple, yet easily manipulated apparatus.
The simplest systems involve the growth of one or more cell types in asingle, perfusedmicroﬂuidic chamber to exhibit the functions of one tis-
sue type. More complex devices can involve multiple cell types that are
separated by porous layers that mimic basal membranes of barrier tis-
sues (Bhatia and Ingber, 2014). These multi-channel chip devices
allow formodels of tissue–tissue or tissue–blood interactions and barri-
er functions and will be the main focus of this review. Additionally,
through the connection of these individual organ-on-a-chip devices, re-
cent studies are showing the possibility to observe organ–organ
crosstalk. Barrier tissues are of great interest to researchers because
they are essential in understanding transport between tissues or tissue
and blood, ADMET (absorption, distribution, metabolism, elimination
and toxicology), and barrier integrity and function. Here, we will inves-
tigate the role of microﬂuidic technologies and other in vitromethods in
themodeling of ﬂuid-to-tissue interfaces from the last few years, specif-
ically with examples in themodeling of skin, lung, gastrointestinal, kid-
ney, endothelium and blood/brain interfaces. We will highlight some of
the recent developments in the ﬁeld, as well as the barriers and chal-
lenges facedwith the adoption of these relatively new technologies. Ad-
ditionally, we will discuss positive trends as well as lessons for future
microﬂuidic and in vitro technologies in the modeling of barrier tissues.
2. Applications
The applications and need for microphysiological devices are po-
tentially far-reaching. These devices may offer improved predictive
power for responses of human tissues compared to currently used
test methods (both cell-based assays and animal testing). Tests
with improved predictive power are desired because current attri-
tion rates in late-stage pharmaceutical testing are high. Based on
the results of pharmaceutical studies from 1960 to 2000, it was de-
termined that 25% of drugs entering clinical development fail due
to lack of efﬁcacy, 20% from toxicology, and 12% due to clinical safety
issues (Kola and Landis, 2004), and testing methods have not
changed signiﬁcantly since then. This year, it was reported by CMR
International that even after the ‘First human dose’ (toxicity testing,
phase I), there is only a 7% chance for a drug tomake it tomarket, and
this only slightly increases to 17% after the ‘First patient dose’ (efﬁca-
cy testing, phase II) (Fig. 1) (CMR International, 2015). By this time, a
large amount of time and money has been invested in the product.
The cost to take a compound from concept to market is on average
$2.5 billion as reported in the Tufts CSDD 2014 cost study, dwarﬁng
the $802 million estimate in its last major study in 2003, even after
being adjusted for post-approval expenses and other costs linked
to approval outside of the US market (DiMasi et al., 2014). Addition-
ally, the time required to bring a drug to market is substantial; 10–
15 years on average. To reach phase I of clinical testing, it takes an av-
erage of 4–6 years (PhRMA, 2015) which goes against the ‘fail fast,
fail cheaply’ goal of pharmaceutical companies in weeding out
ﬂawed products. No company wants to invest millions of dollars only
to ﬁnd that a drug falls ﬂat in clinical trials, or worse yet, after the
drug hits themarket.When comparing ﬁnancial investments to current
attrition rates, it becomes clear thatmore predictive tests need to be im-
plemented. To help direct these studies and possibly eliminate drugs
showing toxicity and/or lack of efﬁcacy early, organ-on-a-chip devices
with human cells could be used in the evaluation of new drug therapies,
vaccines and other biologic agents in a more cost effective, and time ef-
ﬁcient manner during pre-clinical testing.
Additional applications for organ-on-a-chip devices are expansive,
including the assessment of environmental toxin (National Academies,
2014), modeling of disease progression and treatment (Bhatia and
Ingber, 2014; Huh et al., 2012), the advancement of personalized med-
icine through the improvement of screening andmonitoring diagnostics
(Neuzi et al., 2012; Schumacher et al., 2012), and even the development
of vaccines to counter bioterrorism (Wang, 2004). The increased use of
organ-on-a-chip devices in various ﬁelds can ultimately lead to im-
proved pharmaceutical, health and regulatory decisions. The following
Fig. 1. Current trends in pharmaceutical development. A model highlighting the time investment, number of potential compounds and probability of approval at each stage of
pharmaceutical development from the discovery stage to post-approval (based on information from 2015 CMR International Pharmaceutical R&D Executive Summary and the IFPMA
Facts and Figures 2014 report).
32 C.M. Sakolish et al. / EBioMedicine 5 (2016) 30–39section will discuss some of the existing technologies for the in vitro
modeling of barrier tissues on chips.
3. Current Technologies in Chip Design/Culturing Methods
Recent advances in microfabrication techniques have made it possi-
ble to create more sophisticated cell culture environments, capturing
more of the complex function and architecture of organs and tissues
than traditional culturing methods. Often these advanced culturing
methods rely on soft-lithography based PDMS replica molding, a fast
prototyping method that is easily accessible. Many but not all of the
technologies described in this review are based on the soft lithography
of PDMS, however, novel hydrogel materials and plastic materials like
polycarbonate are showing promise and will be discussed as well. The
shape and dimensions of these devices can be easily manipulated to
mimic a variety of organ/tissue microenvironments. The following sec-
tion will review recent technologies in the modeling of human skin,
lung, gastrointestinal tract, kidney, endothelium and blood–brain barri-
er tissues.
3.1. Skin
The skin is commonly referred to as our “largest organ”, serving as a
protective barrier between the human body and surrounding environ-
ment. Understanding skin physiology is necessary in the development
of safe topical products like transdermal drugs and cosmetics, but also
in wound healing, skin disease, infection, scarring and a variety of
other skin conditions. Most in vitromodels of the skin have been static
cultures that emulate the epidermis only, or combine epidermis with
dermis, commonly called “full-thickness skin equivalents” (Black et al.,
1999). Further functionality can be added to these basic models to in-
clude adipose tissue (lipid metabolism, ﬁbroblast and keratinocyte pro-
liferation), vasculature (oxygen and nutrient supply, removal of
metabolites), and even hair follicles (skin metabolism, major penetra-
tion route for topically applied substances) (Atac et al., 2013).
Creating in vitromodels of the skin is challenging, but advances have
been made in reconstructing models in conventional, static growth en-
vironments. Full thickness in vitro skin was created by culturing human
ﬁbroblast cultures (taken from donor skin samples) in a collagen type I
matrix, allowing for the growth of a dermis layer. Once the dermis had
been established, human primary keratinocytes and melanocytes are
then seeded on top of this layer and a differentiated epidermis is
formed, leading to the creation of a human skin equivalent (HSE) com-
posed of associated dermal and epidermal layers reconstructed in vitro.
Results indicated that the epidermis contained 3–4 keratinocyte layersand that there was a clear distinction between dermis and epidermis
(Souto et al., 2006). However, healthy donor skin samples can have
poor donor variation and be difﬁcult to obtain, so in an attempt to mit-
igate this issue, Reijnders et al. have proposed the creation of a HSE ex-
clusively through the culturing of cell lines. In a manner similar to the
previously described HSE creation, ﬁbroblast cell lines were seeded
onto a collagen matrix, and keratinocyte cell lines were seeded on top
of these sheets once ﬁbroblast proliferation had occurred. This artiﬁcial
tissue was found to closely resemble the morphology of native tissues
and primary cultures as conﬁrmed through the formation of multiple
keratinocyte layers and an increase in the expression of inﬂammatory
cytokines and chemokines in response to burn and cold injuries. Addi-
tionally it was noted that re-epithelialization occurred after wounding
events even in the cell line cultures (Reijnders et al., 2015).
Recent developments inmicroﬂuidic technologies havemade it pos-
sible to investigate the effects of shear stress on skin growth. The work
of O'Neill et al. demonstrated that ﬂuid perfusion over keratinocyte cul-
tures increased overall cell viability and conﬂuence compared to static
cultures (O'Neill et al., 2008). A more advanced chip design by Atac
et al. includes two ﬂuidic chambers; the ﬁrst containing skin biopsies
grown over ex vivo subcutaneous tissue (adipocytes, ﬁbroblasts, macro-
phages) in a liquid–air interface chamber, and in the second, submerged
follicular hair extracts (FUEs) (Fig. 2). It was found that integration of
SCT was successful in the chip, while in static cultures, these layers
disintegrated. These results are indicative that dynamic perfusion inﬂu-
ences cell growth and tissue integration. Additionally, hair shaft elonga-
tion was observed in FUEs indicating the possibility of postponing the
catagen phase ex vivo (Atac et al., 2013).
In an attempt to model cross-talk between skin and liver, Wagner
et al. designed amulti-chambermicroﬂuidic devicewith a liquid–air in-
terface for the growth of skin biopsies followed by a second chamber
containing submerged human hepatocytes. All cell types were cultured
within the multi-chamber device in HepaRG medium (supplemented
Williams' medium E). The results showed that the liver chamber not
only produced albumin which was subsequently consumed by the
skin chamber, but equilibrium was reached with virtually no excess al-
bumin in the system within a week of culturing (Wagner et al., 2013).
This indicates crosstalk between organ chambers and opens up the pos-
sibility for a full body-on-a-chip device in the future.
These systems have been validated through testing with well char-
acterized pharmaceutical compounds and shown in vivo-like reactions.
For example, Abaci et al. created aﬂuidic HSE in a design similar to those
previously described with an air interface and ﬂuidic basolateral chan-
nel. To validate the capability of their platform to be used in drug toxic-
ity studies, a clinically relevant dosing of doxorubicin (anti-cancer drug
Fig. 2.Mimicking barrier tissues of organs in microdevices. SKIN CHIP: A series of microﬂuidic chambers were connected to model the skin and hair follicles. A Transwell chamber
contained skin biopsies placed over ex vivo subcutaneous tissue with a ﬂuidic basolateral chamber. A ﬂuidic chamber containing follicular hair extracts (FUEs) followed the skin
chamber in circuit. Reproduced from Atac et al. (2013) with permission of The Royal Society of Chemistry. LUNG/GI CHIP: This chip design was used to model both the lung and GI
barrier tissues. Two ﬂuidic channels run in parallel with a porous membrane to separate epithelium from endothelium. Additionally, empty chambers run along the sides of this device
and pull a cyclic vacuum to mimic movement due to breathing or digestion respectively in lung or GI models. GI model reproduced from Kim et al. (2012) with permission of The
Royal Society of Chemistry. Lung device from [Huh, D. et al. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci Transl Med, 4,
159ra147]. Reprinted with permission from AAAS.
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ture media. Treated cultures displayed spatial detachment at the basal
layer and epidermal-dermal interface. Additionally, no keratinocyte pro-
liferation was observed after treatment (Abaci et al., 2015). Additional
topical (at air interface) or media-dosing toxicity studies could further
validate these models for pre-clinical testing.
3.2. Lung
The blood–air barrier in the lungs exists to prevent air bubbles from
entering the blood, and blood and plasma from entering the alveoli. Ad-
ditionally, this epithelial barrier serves to regulate tissue homeostasis in
the lung, and stabilize the airways and keep them from drying through
the secretion of surfactant ﬁlms. This surfactant layer also protects lung
tissue from harmful particulates. It is thought that abnormal responses
of this epithelial barrier to the surrounding environment (air in the
lungs) heavily contributes to the pathogenesis of chronic airway dis-
eases (asthma, COPD, etc.). However, with a current lack of models
due to differences in human lung morphology, physiology, and immu-
nology from animal models, this barrier tissue is not yet fully
understood.
The majority of in vitro pulmonary tissue models have mainly been
created through the use of Transwells to mimic the air–liquid interface
of lung barrier tissues (Blume and Davies, 2013). However, the use of 2-
layered PDMSmicroﬂuidic devices is increasing. Typical design includes
a top chamber that is air-ﬁlled and permits gas exchange (parenchymal
chamber) and an underlying vascular chamber designed to mimic the
capillary network, allowing for perfusion underneath the cultured tis-
sues (Long et al., 2012). This liquid–air interface is separated by a porous
membrane that allows for cell seeding and growth (Takayama et al.,
2014). The work of Fritsche et al. demonstrated that immortalized
mouse lung epithelial cells could be cultured on the surface of polysty-
rene microcarrier beads and injected into the parenchymal chamber,
allowing for an even distribution of cells on the compartment surface.
Additionally, cell speciﬁcity and functional capacity were demonstrated
through positive staining for alveolar epithelial markers (Fritsche et al.,
2009). Blume et al. used a similar design in their work to model inﬂam-
matory reactions of primary bronchial epithelial cells to pollen (charac-
terized by IL-8 and CXCI release), which had not previously been
observable in static cultures, indicating a higher sensitivity to environ-
mental factors in chip devices with incorporated physiological shear
stress (Blume et al., 2015). Liquid plug propagation was also investigat-
ed in the presence or absence of secreted and added surfactants using
this same design (Tavana et al., 2011). The work of Huh et al. advanced
this 2 channel chip design a step further and cultured vascular endothe-
lial cells in the ﬂuidic chamber on the bottom of the membrane, andalveolar epithelial cells on the membrane in the top channel. This co-
culture allowed for a better formation and mimicking of barrier func-
tion. Additionally, they investigated the role of mechanical strain on
the barrier tissue through the addition of air ﬁlled chambers on the
sides of the channel with vacuum suction to cause slight deformations,
mimicking the stretching of alveolar tissues during normal breathing
(Fig. 2) (Huh et al., 2010).With this unique design, this group alsomim-
icked a drug toxicity-induced pulmonary edema with interleukin-2, in-
dicating the inﬂuence of both ﬂuid ﬂow and mechanical strain on
vascular leakage (Huh et al., 2012).
3.3. GI
The gastrointestinal tract has the largest surface of any tissue within
the humanbody exposed to the external environment. Itsmain function
is selective absorption of nutrients from orally consumed matter, while
maintaining a barrier between this foreign matter and tissues that may
have an inﬂammatory reaction. Low bioavailability (fraction of an ad-
ministered dose of unchanged drug that actually reaches circulation)
of drugs has been one of the major reasons cited for the failure of
novel pharmaceutical compounds entering clinical trials. Unfortunately,
most in vitrodrug/toxicity studies do not address bioavailability of orally
administered drugs because the drug is added directly to tissue, when
by contrast, oral administration is the preferred route. Therefore the
pre-digestion, uptake and transformation of these compounds by the
GI are rarely considered. Another limitation of previous models is the
lack of living microbes on the luminal surface of cultured intestinal ep-
ithelium. Intestinal microbial symbionts contribute signiﬁcantly to in-
testinal barrier function, metabolism, disease, and absorption of
compounds (Round and Mazmanian, 2009; Turner, 2009). Therefore,
testing systems that containmodels of these barrier tissueswith symbi-
onts are invaluable for the correct prediction of drug bioavailability as
early as possible in the drug development process.
In an effort to match the unique 3D shapes of the gut epithelium,
Esch et al. have developed a protocol for the fabrication of a micropo-
rous polymeric membrane from partially polymerized SU8. They dem-
onstrated that when cultured upon substrates with these unique
shapes, Caco-2 cells mimicked key aspects of the gut epithelium. This
technique can create highly controlled shapes allowing for the mimick-
ing of a variety of different barrier tissues (Esch et al., 2012). This 3D ge-
ometry is relevant in the GI tract because cells can localize in different
areas based on scaffold shape. Studies have shown that both protein ex-
pression and differentiation gradients are present in cultures grown on
3D, villus-like geometries, with more columnar and polarized cells near
the top of the villus than in the crypt regions. This follows the observa-
tion that enterocytes becomemore differentiated as theymigrate to the
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bacteria, as many strains preferentially adhere to epithelial cells at var-
ious stages of differentiation (Costello et al., 2014). Works by Kim et al.
have involved the use of 2 channel devices, very similar to those used in
the modeling of lung barrier function, fabricated from PDMS. However,
with this GI barrier, there is medium perfusing in both the top and bot-
tom channels to mimic the barrier between gut epithelium and the
bloodstream. Vacuum chambers were also present along the sides of
these channels to allow for peristaltic-like movement that occurs natu-
rally during digestion (Fig. 2). Co-cultures of gut epitheliumwith intes-
tinal microbe Lactobacillus rhamnosus GG were viable and increased
barrier function as indicated by heightened transepithelial electrical re-
sistance (TEER) in ﬂuidic cultures (static cultures experiences epithelial
detachment). Additionally, TEER was 3–4 fold higher within the chip
device compared to static cultures, nearing in vivo values, and there
was evidence that peristaltic motions increased the permeability of
cell layers without altering TEER, indicating a direct effect on
paracellular mechanisms of transport (Kim et al., 2012). After long-
term culturingwithin this device, macrovilli-like folds formed in epithe-
lial monolayers increasing surface area by over 1.7-fold. Cells expressed
microvilli forming brush borders, and well deﬁned junctions. Cell reor-
ganization also took place, with ratios and localization of absorptive,
enteroendocrine, goblet and Paneth cells similar to those found in vivo
(Kim and Ingber, 2013). These macrovilli and cell organizations have
not been observed under traditional static culturingmethods. Addition-
ally, Mahler et al. created a static, Transwell tri-culture of Caco-2, HT29-
MTX and Raji B cells that mimics the enterocytes, goblet cells, and M
(microfold) cells that populate the healthy intestinal lining. Caco-2
and HT29-MTX cells were seeded in the apical chamber of a Transwell,
and Raji B in the basolateral chamber. This tri-culturingmethod resulted
in a physiologically relevant number of differentiated M cells, which
play major roles in transport and barrier function (Mahler et al., 2012).
Finally, multi-organ systems incorporating the liver have recently
come into focus. Work by Mahler et al. involving a multi-organ system
with gut epithelium and a liver compartment demonstrated a “ﬁrst
pass” metabolism of acetaminophen (APAP) in a gut and liver chamber,
highlighting the importance of pre-digestion and metabolism in the gut
that occurs during oral administration of a drug. It was observed that
within this system, APAP was absorbed and metabolized by the gut epi-
thelium, then went on to be further broken down in the liver compart-
ment, where toxic metabolites formed in a dose-dependent manner
similar to in vivo results (Mahler et al., 2009). In similar work, Esch et al.
coupled a ﬂuidic GI (caco-2/HT29-MTX) and liver (HepG2/C3A) tissue
microphysiological system to investigate the effects of ingested nanopar-
ticles (50 nm) on the liver. Nanoparticles were either added to themulti-
organ system, where they would pass through the GI module prior to
reaching the liver, or to a liver-only control device. The GI module
prevented 90% of nanoparticles from crossing the epithelial barrier, and
the remaining nanoparticles reached the livermodule, causing the release
of aspartate aminotransferase (AST, an injurymarker). This injurywas ob-
servable at lower concentrations thanwas observed in liver-onlymodels,
indicating that compounding effects, or alteration of nanoparticle proper-
ties occurred in the GI module (Esch et al., 2014). In both of these multi-
organ studies, HepG2/C3A and Caco-2/HT29-MTX cells were initially cul-
tured in MEM (Minimum Essential Media) and DMEM (Dulbecco's Mod-
iﬁed Eagle Medium), respectively. However, when cell types were
combined within the multi-organ system, MEM was used throughout.
These couplings of organ-on-a-chip devices allow for more in vivo-like
cell behaviors and properties, but raise questions as to the need of a uni-
versalmedium to support cell function aswell as emulate blood's carrying
capacity for drugs and metabolites.
3.4. Kidney
The kidney ﬁlters compounds from the bloodstream and is one of
the main sites of elimination for drugs circulating in the body.Understanding the barrier functions of the kidney is essential in the de-
velopment of drugs for the lengthening of residence time in the blood-
streamand the subsequent removal of these compounds after they have
taken effect on their target tissues. Additionally, the renal epithelial bar-
rier is heavily involved in the reabsorption of useful compounds like
sugars, salts, small proteins and water. As these compounds are re-
moved from urine precursor, any drugs or compounds left behind are
effectively concentrated, leading tomany unexpected toxic effects. Kid-
ney toxicity is one of the most frequently reported toxic effects during
drug development, and renal toxicity is often only detected late into
clinical trials (Bonventre et al., 2010; Laverty et al., 2011). Therefore
an in vitromodel that takes into effect reuptake in the kidney is essential
in predicting renal toxicity early in the drug development process.
Shear stress plays a major role in renal barrier function as demon-
strated through transcriptomic (gene) and proteomic (protein) analysis
inMDCK (Madin-Darby canine kidney, proximal and distal tubule) cells.
When cellswere grown in a ﬂuidic channel, a signiﬁcant upregulation of
ion transporters involved in calcium, phosphate and sodium homeosta-
sis was observed, as well as genes involved in H+ transport and pH reg-
ulation of the urine. Additionally, there was a noted upregulation in
phase I and II enzymes, multi-drug resistance genes and phase III trans-
porters, allowing for a more in vivo-like metabolism of drugs (Snouber
et al., 2012). Shear stress also plays major roles in protein handling, as
demonstrated by Ferrell et al., who created a multi-layered device (ﬂu-
idic top chamber, media reservoir on bottom, separated by a porous
membrane) to demonstrate albumin handling of renal epithelial cells
under ﬂuidic stress. It was determined that physiological levels of
shear stress signiﬁcantly increased uptake and degradation (metabo-
lism) capacity of cells (Ferrell et al., 2012). Work by Jang et al. using a
similar chip design (Fig. 3) while culturing collecting duct (Jang and
Suh, 2010), distal tubule (Jang et al., 2011), and proximal tubule (Jang
et al., 2013) cells also reported increased effects on the translocation
of aquaporin-2 (AQP2) and reorganization of F-actin in the presence
of shear stress, hormonal stimulation (arginine vasopressin), and an os-
motic gradient compared to static controls. In their studies with proxi-
mal tubule cells, it was also demonstrated that ﬂuid shear stress can
have a protective effect against cisplatin toxicity with a much smaller
degree of LDH release and apoptosis observed in ﬂuidic cultures com-
pared to static controls, resulting in a higher ﬁdelity toxicity response.
In an effort to model proteinuria (high amount of serum in the urine,
normally blocked by the glomerulus), Zhou et al. created a 3D chip
that incorporates layers of BME (basement membrane extract) in a ﬂu-
idic chamber, making it possible to observe EMT (epithelial to mesen-
chymal transition) and the subsequent migration of these cells into
the BME. Cells that were exposed to human serum became apoptotic,
or developed a mesenchymal phenotype, however cells exposed to
heat inactivated serum were unaffected (Zhou et al., 2014). This device
can be used to investigate the roles of EMT in the pathogenesis of renal
ﬁbrosis and loss of barrier function. Finally, in a move away from PDMS
devices, ﬁbrillogenesis of collagen in a liquid molding technique has re-
cently been investigated for applications in nephronmodeling. Mu et al.
have developed a collagen and alginate device that contains twoparallel
tubes (vascular and nephron) that allow for passive diffusion through
the device material (Mu et al., 2013). Additionally, renal epithelial
cells were able to seed on all internal surfaces of the channel, whereas
cells do not naturally “stick” to PDMS. This device design shows much
promise for future applications in the modeling of barrier tissues due
to the more realistic ECM-like material and possibility for passive diffu-
sion between parallel channels, while still maintaining the separation of
tissues.
Finally, a microﬂuidic model of the kidney (MDCK) has been com-
bined with a model of the liver (HepG2/C3a or HepRG) in order to ob-
serve the synergistic interaction between these organs in the presence
of ifosfamide (an anticancerous drug), which, when metabolized,
forms a nephrotoxic compound, chloroacetaldehyde. Fluidic cultures
of HepaRG, and HepaRG/MDCK co-cultures were grown in HepaRG
Fig. 3.Mimicking barrier tissues of organs inmicrodevices. KIDNEY CHIP: Kidney tubular epithelial cells were seeded onto an ECM-treatedmembrane in a ﬂuidic, top channel. Underneath
themembrane was a media reservoir to provide nutrients to the basolateral surface of the cell monolayer. Reproduced from Jang and Suh (2010) with permission of The Royal Society of
Chemistry. ENDOTHELIUM CHIP: Fully enclosed, perfusable vessels formed in a collagen hydrogel. This hydrogel allows for endothelial growth on all internal surfaces of the vessel,
allowing for a close recapitulation of blood vessel formation. Adapted by permission from Macmillan Publishers Ltd.: [NATURE PROTOCOLS] (Morgan et al., 2013), copyright (2013).
BLOOD–BRAIN CHIP: A multi-layered microﬂuidic device with incorporated electrodes for internal TEER measurements. Astrocytes and brain endothelial cells were seeded on opposite
sides of the membrane in a back-to-back co-culture resulting in higher resistance to permeability and barrier function than endothelial monocultures. Reproduced from Booth and Kim
(2012) with permission of The Royal Society of Chemistry.
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inMEM. Ifosfamide (50 μM)was either added to the ﬂuidic multi-organ
device, or to a kidney only device to validate this metabolic model. After
a 72 h exposure, no nephrotoxic effects were observed in the kidney-
only devices, however the kidney cells in the multi-organ device exhib-
ited cell death, and an increased release of intracellular calcium indicat-
ing cell distress caused by the formation of toxic metabolites (Choucha-
Snouber et al., 2013). This studyhighlights the need formulti-organ sys-
tems that address systemic organ-organ interactions, whichmay poten-
tially allow for more effective predictive toxicology models than single-
tissue systems.
3.5. Endothelium
The vascular system provides the perfusion of blood, containing nu-
trients and drugs to tissues and organs, while also removing waste and
metabolites. Blood vessels are an integral part of the body and serve as a
connection for all tissues and organs, with a low and selective perme-
ability to ﬂuid and solutes under normal physiological conditions. Addi-
tionally, the endothelial barrier in these vessels mediates the transfer of
solutes and cells between the bloodstream and surrounding tissues,
playing a central role in the regulation of metabolic activity, wound
healing, immune response and disease progression. However, the
breakdown of this barrier can lead to edema (leaking of watery ﬂuids
into surrounding tissues) and inappropriate interstitial forces. The en-
dothelium is also of interest in the study of tumor metastasis, due to
tumor cell interactions with endothelial barriers during organ invasion.
It is therefore important to understand the functions of the endothelium
to maximize selective drug delivery and the understanding of disease
mechanisms.
Van der Meer et al. demonstrated that it is possible to control the
shapes of vessel networks in addition to shear stress through their
growth in PDMS channels within a microﬂuidic device. HUVECs and
pericytes (10:1) were seeded into PDMS channels with collagen type I
and within 12 h, formed tubular-like structures, following the contours
of the microﬂuidic channels (van der Meer et al., 2013). There has also
been evidence of cross-talk between endothelial cells and their sur-
rounding tissues in unique cell–cell interactions. Chen et al. fabricated a
bi-layer PDMS microﬂuidic device for the co-culture of porcine valvular
endothelial cells (VECs) and valvular interstitial cells (VICs). The ﬂuidic
chamber on top contained VECs seeded on a ﬁbronectin treated mem-
brane, and the bottom chamber (static) contained VICs encapsulated ina methacrylated gelatin hydrogel. Utilizing this device, it was possible
to investigate the roles of both shear stress andVEC co-culture on the dif-
ferentiation of VICs to myoﬁbroblast phenotypes. It was observed that
the presence of endothelial cells signiﬁcantly decreased VIC differentia-
tion (78% VICs alone, 29% co-culture) and that the introduction of rele-
vant shear stress to the ﬂuidic chamber enhanced this effect (17%
differentiation of VICs) (Chen et al., 2013). Therefore, both bio-
mechanical and -chemical signaling factors must be considered in the
design of healthymicrovessels. In addition, Douville et al. have described
a method for creating a 2-layer PDMS microﬂuidic device with embed-
ded electrodes for the purpose of evaluating endothelial barrier function
without disrupting cell growth. This device was tested with brain and
kidney endothelial cells, aswell asmyoblast cells. Clear differences in ep-
ithelial resistance were observed in these various cell types, indicating
proper cell growth and electrode function. Additionally, readings
responded in real-time to changes in TEER as indicated by signiﬁcant
drop-offs when TritonX100 permeabilizing agent was added to culture
media (Douville et al., 2010).
In an attempt to replace PDMS, a number of endothelial barrier
modelswere created in collagen hydrogel channels.Morgan et al. devel-
oped a procedure for creating 3D cell cultures in collagen hydrogel,
leading to fully enclosed perfusable vessels in an easily manipulated
matrix (Fig. 3) (Morgan et al., 2013). HUVECs were successfully grown
within these enclosed channels and displayed appropriatemorphology,
barrier function, angiogenic remodeling, and cell–cell junctions. In addi-
tion to modeling a relevant ECM, Price et al. investigated the effects of
mechanical signals (shear stress, transmural pressure, and luminal pres-
sure) on barrier function andmicrovessel stability with BECs (endothe-
lial cells from human dermal blood microvessels). Results of these
studies indicated that high shear stress (15–20 dyn/cm2) lead to barrier
function comparable to that observed in vivo, and a 2-fold increase in
longevity over studies with low shear stress. Additionally, positive
transmural pressure was associated with vessel stability, resulting in a
much lower degree of endothelial delamination than controls (Price
et al., 2010). These porous materials also allow for investigations into
angiogenesis and endothelial sprouting. Verbridge et al. created 3 paral-
lel channels in collagen hydrogel. The central channel contained endo-
thelial cells, with the neighboring channels serving as a source and
sink for a VEGF biochemical gradient. This gradient promoted endothe-
lial sprouting and invasion into the surrounding collagen matrix which
would not be possible with less porous materials like PDMS (Verbridge
et al., 2013). These in vitro models demonstrate controlled vessel
Fig. 4. Physiologically-based pharmacokinetic (PBPK) model of a human system. This
model shows the blood circulation throughout the human body through various tissues.
Future multi-organ microﬂuidics will likely be designed following this type of schematic,
with various residence times and permeability in each organ chamber.
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and a viable method for studying barrier function without disrupting
cell layers. Additionally, the move to more porous materials like
hydrogels allows for more accurate drug transport and diffusion across
endothelial barriers and ECM.
3.6. Blood–Brain
The blood–brain barrier is a highly selective (metabolic and bio-
chemical) blockade against the entry of substances into the brain tissue.
This makes drug development targeting brain disease extremely difﬁ-
cult because passive diffusion across this membrane is almost non-
existent with the exception of small molecules (b500 Da), which have
had little/poor response in the treatment of most diseases (Pardridge,
2003). Additionally, this barrier protects the brain against ﬂuctuations
in plasma composition, maintains parenchymal homeostasis and trans-
port through unique, asymmetrically expressed carrier-mediated trans-
membrane transport systems. Due to the fact that there are a lack of fen-
estrations and a very small amount of pinocytosis in the endothelial
cells lining this barrier, in vitromodeling could allow for a greater un-
derstanding and testing of innovative methods for drug delivery that
exploit existing carrier-mediated transport systems.
Considering that themajority of in vivo drug transport studies are on
mice (current in vitro models use rat, bovine or porcine endothelial
cells), Shayan et al. developed amurinemodel of the blood–brain barri-
er. This co-culture involved murine BMECs (brain microvascular endo-
thelial cells) cultured with rat primary astrocytes. These static,
Transwell models involved either a back-to-back co-culture of cells (en-
dothelial cells on top, and astrocytes on the bottom of the membrane)
or control cultures with astrocytes grown in a separate well. It was de-
termined that back-to-back cultures displayed higher TEER and lower
permeability to sodium ﬂuorescein. Additionally, an overall 2.5-fold in-
crease in functional proteins and transporters was observed bywestern
blotting, and in a series of tests with hydrophobic and hydrophilic
drugs, an overall correlation of 0.98 was determined in comparison to
in vivo permeability values (Shayan et al., 2011a). In later work, it was
also demonstrated with the same Transwell culturing method that
back to back culturing of astrocytes with BMECs can increase TEER of
the endothelial cells by up to 167%, and that this increase is speciﬁc to
BMECs only, as the addition of astrocytes to aortic endothelial cells
had no effect on TEER (Shayan et al., 2011b). In similar work, Booth
et al. cultured brain endothelial cells in the presence and absence of as-
trocytes in a ﬂuidic multi-layered PDMS device with integrated TEER
electrodes tomeasure barrier function (Fig. 3). Dynamic ﬂowwas intro-
duced in both the top and bottom ﬂuidic channels, and astrocytes and
endothelial cells were seeded on opposite sides of the membrane be-
tween the ﬂuidic channels, resulting in a back to back co-culture. Epi-
thelial resistance of the blood–brain barrier within the ﬂuidic device
was much higher than values observed in back-to-back static control
Transwell cultures (25 vs 250 Ω ∗ cm2 in controls against chip devices
respectively), indicating a strong inﬂuence of shear stress on epithelial
barrier function. Additionally, these TEER results were conﬁrmed
through permeability studies with ﬂuorescent dextrans, resulting in a
signiﬁcantly higher permeability in static controls and ﬂuidic endothe-
lial mono-cultures compared against ﬂuidic co-cultures (Booth and
Kim, 2012). Griep et al. also conﬁrmed these modulations in epithelial
resistance caused by the introduction of a dynamic ﬂuidic environment
through the use of an immortalized human brain cell line (hCMEC/D3)
in a similar device design (Griep et al., 2013). Finally, work by Achyuta
et al. combined neural cells obtained from primary rat cortical tissue
(4% neurons, 95% astrocytes, and 1% microglia) with neurovascular
cells (RBE4) in a multi-layered PDMS microﬂuidic device. Vascular
cells were cultured in the ﬂuidic top chamber, and neural cells in the
bottom, static reservoir of the device. After 10 days of culture, neural
cells showed evidence of ﬁring inhibitory and excitatory potentials,
and endothelial cells expressed von Willebrand factor (vWF), ZO-1tight junctions, and diluted-acetylated low density lipoprotein (dil-a-
LDL) uptake. These results, in combination with a reduced permeability
of dextran across the endothelial barrier indicate recapitulation of the
functions of “Neurovascular Units” (Achyuta et al., 2013). The results
of these studies are promising, providing for unique opportunities in
the in vitro study of nutrient, therapeutic agent, and nanomaterial deliv-
ery across this highly selective barrier tissue. However, although the co-
culture of brain endothelial cells with astrocytes has a synergistic effect
on the overall TEER and decreased permeability of this barrier tissue,
limitations still remain with these models. Due to the low availability
of human brain cells, and the low yield of BMEC isolations from animal
subjects, many singular cell isolations must be performed for model
scalability. Additionally, many of the models described above involve
mixed species co-cultures of BMECs and brain cells, which is suboptimal
compared against syngeneic co-culturing. With recent advances in the
use of neural progenitor cells (NPCs) and human pluripotent stem
cells (hPSCs), an all-human in vitro BBB model might soon be possible
(Lippmann et al., 2011).
4. Advantages Over Current Methods
The use of microﬂuidic-based in vitro modeling has many advan-
tages over traditional testingmethods for clinical studies. In comparison
to static in vitro culture, microﬂuidics allow for dynamic ﬂuid ﬂow
through cultures. This highly controlled dynamic cell growth environ-
ment has been linked to increased cell growth, differentiation, and po-
larization, allowing for more in vivo-like tissue growth and behavior
(Jang et al., 2011). Additionally, ﬂuid ﬂow enables ADMET properties,
allowing for more accurate predictions of physiologically based phar-
macokinetic (PBPK) properties than with static systems. The combina-
tion of microﬂuidics with this in silicomodeling has the possibility for
more accurate efﬁcacy and toxicity predictions (Fig. 4). Fluid ﬂow has
also been linked with longer culture periods, up to a month as shown
in microﬂuidic modeling of lung tissue (Huh et al., 2010). This allows
for more clinically relevant time scales as many diseases develop over
chronic exposure, or can take time to express symptoms. Microﬂuidics
by deﬁnition also utilize smaller media volumes than static cultures in
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same area of cells. This ratio of ﬂuid to tissue is a closer match to that
found in the body, and leads to a smaller reagent requirement, reducing
cost and maximizing information obtained from valuable samples early
on in the drug development process. Finally, microﬂuidic chambers
allow for the possibility of tissue/organ interconnection. Fluidic cham-
bers can be connected to one another, allowing for a degree of ﬂuidic in-
teraction and cell signaling while maintaining physical separation, an
application that is not currently possible in static cultures. Microﬂuidic
in vitromodeling also has many advantages over in vivo animal studies.
One of the greatest ﬂaws in animal testing is the questionable corre-
lation of animal data to human systems. This often results in either a
lack of efﬁcacy or unexpected toxicity when transitioning from animal
studies to human clinical trials. The use of in vitromicroﬂuidic devices
has the potential to overcome this issue through the use of human
cells or tissues (in the case of tissue explants) in physiologically relevant
microenvironments. By matching the growth environment of these tis-
sues within amicroﬂuidic device, it is possible to observe potential drug
interactions as they would translate to human systems, potentially
allowing for much better drug efﬁcacy and toxicity predictions. Addi-
tionally, imaging ismuch simpler inmicroﬂuidics due to the transparent
nature of many fabrication materials, and the control of tissue and cell
positioning which is not possible in living systems. This allows for real
time imaging under ﬂow without disrupting cell growth. Microﬂuidics
also allow for high throughput sample processing and more realistic
sample sizes than with animal studies, where it can be time consuming
and expensive to obtain a large sample of animal specimens. This
throughput is perhaps one of the greatest advantages of the use of
microﬂuidic technologies. Through the use of multi-organ systems like
those described in this paper, it is possible to simultaneously assess
the effects or toxicity of drugs and their metabolites on multiple tissue
types, further reducing testing times. This type of high throughput anal-
ysis can allow for rapid, inexpensive and highly efﬁcient testing. Addi-
tionally, it is possible to incorporate systems to monitor tissue and
barrier health (TEER, automatic sampling, etc.) within these engineered
devices, streamlining the testing process even further. Finally, many pa-
thologies of toxicity and disease are poorly understood on molecular
and biochemical levels which are challenging if not impossible to ob-
serve at themacro scalewithin a living system.Microﬂuidics offer an al-
ternative at a small enough scale, where cell–cell or cell–tissue
interactions can be simpliﬁed and accurately emulated, allowing for
easily observable interactions.
5. Limitations
Though the use of organ- or tissue-on-a-chip devices shows a great
deal of promise for future applications, it is important to remember
that these are relatively new technologies and require further advance-
ments prior to widespread use. It is ﬁrst necessary to characterize these
deviceswith drugs that havewell studies ADMET properties, and to val-
idate the relevance to clinical efﬁcacy and toxicity. Additionally, the de-
vices that are currently being used in the lab are labor intensive to
create, and require specialized training to maintain. There are many
technical challenges with fabrication processes, issues with bubbles
and ﬂow perturbations that can destroy cell cultures, and issues with
cell contamination in porous microﬂuidic devices. The use of a rocker
platform or a gravity-driven ﬂow can aid in the elimination of bubbles
for somemicroﬂuidic platforms, however this solution does not address
unidirectional shear ﬂow (Sung et al., 2010; Esch et al., 2015). Addition-
ally, consistent cell seeding can be difﬁcult to achieve within complex
channel designs, and the simpliﬁed ECMs commonly used in culturing
can lead tomatrix degradation or contraction. To create amore complex
ECM, some groups have used Matrigel, however this ECM is derived
from tumor cells and is highly dissimilar to normal cell ECM and can
have a high batch-to-batch variance. In addition to ECM, cell media
does not reﬂect in vivo context, and can also impact cell phenotype(Kolbe et al., 2011). In order for these technologies to transition to in-
dustrial and clinical use, it is necessary to create “user friendly”, robust
and scalable testing systems.
In addition to concerns with fabrication and cell maintenance, there
is a consensus among all researchers that no in vitro culture will ever
completely represent the complexity of whole animal systems. The
feedback mechanisms of extensive interrelationships and crosstalk
frommultiple cell types and dynamics that modulate physiological pro-
cesses are currently very difﬁcult to recapitulate in vitro. Additionally,
adaptive immune responses, and complex system-level behaviors of
the endocrine, skeletal and nervous system have not yet been investi-
gated (Astashkina et al., 2012). Finally, there will always be an issue of
systematic, “off target” toxicity. In vitro studies often involve just a few
cell or tissue types at most, but often toxicity can crop up in areas of
the body that weren't necessarily a “target” of the drug being intro-
duced. As a result of these limitations, in vivo animal studies retain the
advantage of possibly uncovering such off target responses. However,
with differences in animal and human physiology, such results are
often not predictive of human response. Using such animal studies to
suggest which organ compartments need to be added to the in vitro
humanmodel should be valuable. Chip devices need to make many ad-
vancements beforemodeling full tissue or organ level functions, butwill
have many exciting applications for future drug discovery, and disease
modeling and treatment.
6. Outstanding Questions
In addition to the limitations mentioned above, there are a few out-
standing questions that must be addressed prior to the widespread use
of lab-on-a-chip devices. Theﬁrst, andmost concerning is: Can thesede-
vices really mimic organ level functions and interactions? Macro-scale
architecture, and micro-scale spatial heterogeneity found in organoids
and tissue sections can be very difﬁcult to recapitulate in microﬂuidic
channels, but play large roles inmany physiological functions. Addition-
ally, how canwe account for the function of organs regulated by humor-
al, neurogenic, and metabolic factors? With existing organ on a chip
technology, these factors can only be fully accounted for in whole-
body, in vivo animal models.
Wemust also consider the availability of relevant human cells. It can
be difﬁcult to obtain healthy primary cells from a diverse population, so
an alternative must be considered. Recently, it has been suggested that
human induced pluripotent stem cell technologies could be utilized to
provide relevant cell models, additionally establishing the possibility
for personalized medicine (Williamson et al., 2013; Bellin et al., 2012).
Cell availability is not only an issue with healthy tissue modeling, but
must also be considered in disease modeling. Can a cell phenotype be
discerned that represents the pathophysiology of underlying diseases?
Further along this avenue, can a phenotype be altered in vitro in such
away that potential therapiesmight emerge? Another imperative ques-
tion iswhether it will be possible to develop a universal blood substitute
for microﬂuidic culturing (Schaffner et al., 1995; Guo et al., 2011). Cur-
rently used media have been optimized for speciﬁc cell types, but in
order to see tissue–tissue interactions in more complex multi-organ
chamber devices, it will be necessary to have a universal solution that
will equally supplement multiple cell types. The papers referenced ear-
lier in this review that incorporated multiple cell/tissue types into
multi-chamber devices faced this very issue and offer potential models
to solve these problems. Questions pertaining to device fabrication ma-
terials have also been of recent concern. There has recently been a push
toward thermoplastic materials (polystyrene, cyclic oleﬁn copolymer,
polymethyl methacrylate, polycarbonate) over elastomers (PDMS),
which are used in the majority of organ-on-a-chip devices because of
their low cost, high availability and ease of use in soft lithography. Re-
cent studies have determined that elastomer materials can leach
uncrosslinked oligomers into solution, absorb small molecules (affect-
ing cell signaling, and pharmaceutical dosage), and have higher vapor
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nanoliter ﬂuid volumes) (Toepke and Beebe, 2006; Regehr et al., 2009).
Finally, when considering device design, it is important to ask: What
types of real-time detection and analysis can be incorporated into chip
devices? Many of the works described in this review have incorporated
TEER, and ﬂuorescent or optical based measurements, however many
recent advances in label-free protein assays have been reported. Electri-
cal biosensors and automated sampling for label-free detection of pro-
tein and disease biomarkers have proven to be useful, however their
incorporation into chip systems has not yet been investigated (Luo
and Davis, 2013). Additionally, the use of universal assays will need to
be incorporated at a larger scale. Current assays generally focus on cell
function and behavior, but organs and tissues also need to be evaluated
at a functional level. As an example, Stancesu et al. monitored the con-
tractile stress of human cardiomyocytes and used Multi-electrode ar-
rays (MEAs) to measure electrical activity in an in vitro model of the
heart. This data, coupled with cell-based assays could provide relevant
predictions for drug toxicity and efﬁcacy ranging from cell–cell to sys-
temic scales (Stancescu et al., 2015). It is also important to consider,
when designing these monitoring and testing methods that with low
cell culture volume and cell count compared to traditional culturing, it
might be difﬁcult to detect biological signals at this scale. These sensors
will be required to have high sensitivity to detect changes in biological
responses. Ultimately, the main question to be asked is: which is more
important, complexity or practicality? It may, in the future, be possible
to design whole-body microﬂuidics that can account for systemic
organ interactions and signaling, and parallel the function of the
human body, but would this sort of system be practical? Themore intri-
cate the device becomes, the more difﬁcult it becomes to manufacture,
distribute, and train operators. A reason balance between these two op-
posing forcesmust be reached in order for the creation of a practical, yet
insightful technology to be widely utilized.
Once these questions have been addressed, microﬂuidic-based chip
technologies have the potential for extensive breakthroughs in drugdis-
covery, disease modeling and furthering our understanding of organ
and tissue interactions within the human body. This novel modeling
technology has many interesting applications that are just beginning
to be explored. For example, disease modeling has already been
highlighted, but further along that route is understanding cancer forma-
tion and metastasis. It is currently understood that cancer growth and
spread is not only affected by the surrounding chemical environment,
but also the surrounding ECM and mechanical factors such as shear
stress which can easily be manipulated in microﬂuidics (Chivukula
et al., 2015). Additionally, the study of many rare diseases may be pos-
sible. These diseases often have small sample populations for study
and therefore suffer from a low availability for in vivo studies. If replicat-
ed in vitro, it may be possible to study amuch larger population size and
gain insight into some of themechanisms of these diseases. Another in-
teresting application is for stratiﬁed medicine—developing a drug for a
particular set of the population, rather than a “one size ﬁts all” approach
to medical treatments (Trusheim et al., 2007). For example, treatments
could be developed based on the presence or absence of particular bio-
markers. High throughput testing methods, like the use of microﬂuidic
in vitromodels, will assist greatly in the development of these stratiﬁed
treatments at the pharmaceutical development and testing stages. Ad-
ditionally, these technologies have applications in predicting appropri-
ate drug doses or administration regimens to achieve desired effects
prior to clinical dosing tests. Finally, the study of nervous, endocrine,
sensory, and reproductive systems for whichwe currently lack dynamic
models will likely be of focus in the near future.
Understanding how barrier tissues function is essential for the de-
sign of effective pharmaceutical compounds. Once these devices are
transitioned from research to clinical use, and we have more accurate
predictive models early on in the development process, we will likely
see an end to the recent stagnation in pharmaceutical development. Ad-
ditionally, once pluripotent stem cells are incorporated into thesetechnologies, there will presumably be a huge push for use of organ-
or body-on-a-chip devices in personalized medicine, allowing for
patient-tailored disease treatments and diagnostic testing. Overall, the
ﬁeld of in vitro modeling, and many others will greatly beneﬁt from
the widespread use of organ-on-a-chip devices as we move into the
future.
7. Search Strategy and Selection Criteria
Material for this review was selected through searches on PubMed,
MEDLINE, and from references contained in relevant articles, using the
search terms: “microﬂuidics”, “microphysiological”, “lab-on-a-chip”,
“in vitro modeling”, and “barrier tissues” in their applications for the
modeling of the tissues discussed in this review. Only articles published
in English were selected, with a focus on articles published after 2010.
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